Barclays PLC Cyclerion Therapeutics, Inc. Transaction History

Barclays PLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$1.56 - $2.99 $3,591 - $6,882	-2,302 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$2.73 - $4.13 $5,773 - $8,734	-2,115 Reduced 47.88%	2,302 $7,000
Q2 2021 Aug 13, 2021	SELL	$2.18 - $4.29 $30,735 - $60,484	-14,099 Reduced 76.14%	4,417 $17,000
Q1 2021 May 13, 2021	BUY	$2.69 - $5.12 $30,577 - $58,199	11,367 Added 159.0%	18,516 $52,000
Q4 2020 Feb 11, 2021	SELL	$2.25 - $7.12 $6,797 - $21,509	-3,021 Reduced 29.71%	7,149 $22,000
Q3 2020 Nov 12, 2020	SELL	$3.46 - $8.39 $10,424 - $25,279	-3,013 Reduced 22.86%	10,170 $62,000
Q2 2020 Aug 12, 2020	BUY	$2.37 - $7.14 $12,688 - $38,227	5,354 Added 68.39%	13,183 $77,000
Q1 2020 May 13, 2020	SELL	$2.46 - $5.84 $38,838 - $92,201	-15,788 Reduced 66.85%	7,829 $20,000
Q4 2019 Feb 10, 2020	BUY	$1.8 - $13.43 $21,288 - $158,836	11,827 Added 100.31%	23,617 $64,000
Q3 2019 Nov 14, 2019	SELL	$8.12 - $14.54 $27,875 - $49,915	-3,433 Reduced 22.55%	11,790 $143,000
Q2 2019 Aug 14, 2019	BUY	$9.6 - $22.85 $146,140 - $347,845	15,223 New	15,223 $174,000

293K

Ticker CYCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,479,800
Market Cap $145M
Description
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.